论文部分内容阅读
Kanis等认为潘米双磷酸钠(pamidronate)的降血钙作用超过我们报道的氯甲双磷酸钠(clodronate)。推测可能是高血钙发生机理的不同而致反应不同,或由于氯甲双磷酸钠的剂量较低(一次仅输注600mg)所致。作者发现恶性肿瘤并体液性高血钙患者对溶骨抑制剂的疗效比局部溶骨性高血钙者为小。然而,我们观察到的这种疗效上的区别,并不归因于高血钙发生机理的不同,因为我们的3种方案治疗组中,肿瘤类型的分布是相似的。
Kanis et al. suggested that the calcium lowering effect of pamidronate was greater than that reported by clodronate. It is presumed that the mechanism of hypercalcemia may be caused by different reactions, or due to the lower dose of sodium clotridiphosphate (infusion of only 600mg at a time). The authors found that patients with malignant tumors and humoral hypercalcemia were less effective against osteolytic inhibitors than those with local osteolytic hypercalcemia. However, the difference in efficacy observed by us was not attributable to the difference in the mechanism of hypercalcemia, because the distribution of tumor types was similar in our three treatment groups.